Patient who is pregnant and/or breastfeedingXx_NEWLINE_xXPregnant or lactating womenXx_NEWLINE_xXWoman who are pregnant or breastfeedingXx_NEWLINE_xXTREATMENT: PregnantXx_NEWLINE_xXPregnant or breastfeedingXx_NEWLINE_xXPregnant women are eligible to participate in this studyXx_NEWLINE_xXFemales who are pregnant or breastfeeding are ineligibleXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drugXx_NEWLINE_xXBreastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drugXx_NEWLINE_xXPregnant women are excluded from this studyXx_NEWLINE_xXTUMOR BIOPSY SEQUENCING: Women who are pregnant or breastfeedingXx_NEWLINE_xXTREATMENT: Breastfeeding should be discontinued while the patient is on this trial and for 30 days following last dose of study drugXx_NEWLINE_xXTREATMENT: Women who are pregnant or breastfeedingXx_NEWLINE_xXWomen who are pregnant or breastfeedingXx_NEWLINE_xXPregnant and breastfeeding women are excluded from this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant or breastfeeding womenXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drugXx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drugXx_NEWLINE_xXIf pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-3475Xx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with dabrafenib/trametinibXx_NEWLINE_xXPregnant women and women who are breastfeeding are excluded from this studyXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinuedXx_NEWLINE_xXPregnant women are excluded from this studyXx_NEWLINE_xXNot pregnant or nursing, with negative serum pregnancy test; pregnant women are excluded from this study; breastfeeding should be discontinued; timeline: within 3 weeks prior to enrollmentXx_NEWLINE_xXPregnant womenXx_NEWLINE_xXPregnant women and women who are breastfeeding are excluded from this studyXx_NEWLINE_xX